Renaissance Technologies LLC Acquires New Holdings in UroGen Pharma Ltd. (NASDAQ:URGN)

Renaissance Technologies LLC purchased a new stake in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 138,200 shares of the company's stock, valued at approximately $1,472,000. Renaissance Technologies LLC owned about 0.59% of UroGen Pharma as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. Legal & General Group Plc raised its stake in shares of UroGen Pharma by 24.6% during the fourth quarter. Legal & General Group Plc now owns 19,845 shares of the company's stock valued at $211,000 after acquiring an additional 3,920 shares during the last quarter. Wells Fargo & Company MN increased its holdings in UroGen Pharma by 2.7% during the 4th quarter. Wells Fargo & Company MN now owns 221,540 shares of the company's stock valued at $2,359,000 after purchasing an additional 5,801 shares during the period. ExodusPoint Capital Management LP purchased a new stake in UroGen Pharma in the 4th quarter worth approximately $358,000. Geode Capital Management LLC lifted its holdings in UroGen Pharma by 1.4% in the 4th quarter. Geode Capital Management LLC now owns 461,902 shares of the company's stock worth $4,919,000 after buying an additional 6,265 shares during the period. Finally, Alliancebernstein L.P. grew its position in shares of UroGen Pharma by 751.5% in the 4th quarter. Alliancebernstein L.P. now owns 199,259 shares of the company's stock worth $2,122,000 after buying an additional 175,859 shares during the last quarter. Hedge funds and other institutional investors own 91.29% of the company's stock.

Insider Buying and Selling at UroGen Pharma

In related news, General Counsel Jason Drew Smith sold 7,379 shares of the firm's stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the sale, the general counsel now owns 26,468 shares of the company's stock, valued at $294,853.52. This trade represents a 21.80 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Mark Schoenberg sold 4,551 shares of the company's stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the completion of the transaction, the insider now directly owns 145,666 shares in the company, valued at $1,622,719.24. This trade represents a 3.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.10% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of analysts recently commented on the company. D. Boral Capital reaffirmed a "buy" rating and issued a $25.00 price target on shares of UroGen Pharma in a research note on Monday. Scotiabank assumed coverage on shares of UroGen Pharma in a research note on Wednesday, April 16th. They set a "sector outperform" rating and a $23.00 target price on the stock. LADENBURG THALM/SH SH initiated coverage on shares of UroGen Pharma in a research note on Wednesday, February 19th. They issued a "buy" rating and a $31.00 price target for the company. HC Wainwright restated a "buy" rating and issued a $55.00 price objective on shares of UroGen Pharma in a report on Monday. Finally, Guggenheim reissued a "buy" rating on shares of UroGen Pharma in a research report on Tuesday. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $32.86.

UroGen Pharma Stock Down 2.0 %

Shares of URGN traded down $0.23 during mid-day trading on Thursday, reaching $11.41. The company had a trading volume of 534,142 shares, compared to its average volume of 532,008. UroGen Pharma Ltd. has a 52 week low of $8.94 and a 52 week high of $20.70. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00. The company has a market capitalization of $525.93 million, a price-to-earnings ratio of -3.62 and a beta of 0.80. The firm has a 50-day moving average price of $10.47 and a 200 day moving average price of $11.08.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last released its earnings results on Monday, March 10th. The company reported ($0.80) EPS for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.11). The firm had revenue of $24.57 million during the quarter, compared to analysts' expectations of $25.25 million. On average, sell-side analysts forecast that UroGen Pharma Ltd. will post -3.12 EPS for the current year.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.